PERCEVAL Pivotal Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The clinical investigation is designed as a prospective and non-randomised study on a maximum of 150 patients. This study will be conducted at Investigational Centres in the European Community. A minimum number of 8 European Centres will be involved in the clinical investigation. A minimum of 15 patients will be enrolled at each Investigational Centre. The clinical follow-up requires evaluations at discharge (or 30 days if the patient is still hospitalized), 3-6 and 12 months following the procedure.The primary objective of this clinical investigation is to assess the performance of the Perceval S valve at 3-6 months after implantation in high surgical risk patients, who require a surgical intervention to replace the aortic valve.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perceval S Aortic Heart Valve Study- North America

NCT01810679

Aortic Valve Stenosis Aortic Valve Stenosis With Insufficiency Regurgitation, Aortic Valve +1 more

TERMINATED NA

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

NCT01240902

Severe Aortic Stenosis

COMPLETED NA

Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve

NCT00630916

Heart Valve Diseases

COMPLETED NA

Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)

NCT04983823

Heart Failure

RECRUITING NA

Clinical Evaluation of Percutaneous Implantation of the Medtronic CoreValve Aortic Valve Prosthesis (18Fr-Study)

NCT01051518

Aortic Valve Stenosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The design of the Perceval S prosthesis stems from the intention to offer an alternative to traditional flexible prostheses (stented and stentless biological valves) using conventional open-heart surgery. As a result of the sutureless implant procedure, in fact, patients could benefit from:

Reducing aortic clamp times, with subsequent overall reduction of surgical timing and therefore reduction in related risks; Avoiding to pass the stitches through the annulus and sutures knotting, with consequent less risk of tearing aortic annulus and wall, damaging the bundle of His, embolizing foreign material in the vascular system.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Replacement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Perceval S

Group Type EXPERIMENTAL

Aortic valve replacement with Perceval aortic heart valve

Intervention Type DEVICE

Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aortic valve replacement with Perceval aortic heart valve

Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of 75 years or older;
* Subjects with aortic valve stenosis or steno-insufficiency;
* Subjects at high surgical risk and candidates for aortic valve replacement with a biological prosthesis;
* Subjects in NYHA functional classes III and IV with the Logistic EuroSCORE greater than 5%.
* Subjects who have agreed to participation in the clinical evaluation and who have signed the informed consent;
* Subjects who are willing to undergo all the medical follow-ups and echocardiographic examinations and laboratory tests that form part of this present protocol.

Exclusion Criteria

* Subjects involved in any other clinical study for drugs or devices;
* Subjects who have previously undergone implantation with the Perceval S prosthesis being assessed;
* Subjects with previous implantation of valve prostheses or annuloplasty ring in mitral position;
* Subjects requiring simultaneous procedures, apart from septal myectomy and/or coronary by-pass;
* Subjects with aneurysmal dilation or dissection of the ascending aortic wall needing surgical correction;
* Subjects needing non elective intervention;
* Subjects with aortic annulus (after procedure for decalcification) of dimensions such that the implantation of a valve of size 21 or 23 mm is not possible (direct intra-operative measurement with sizer), in accordance with the indications reported in the Investigator's Brochure;
* Subjects with active endocarditis;
* Subjects with active myocarditis;
* Subjects with any anomaly of the coronary ostia determined through pre-operative coronary angiogram or during intervention itself;
* Subjects with congenital bicuspid aortic valve;
* Subjects with aortic root enlargement, where the ratio between observed and expected diameters (calculated as a function of age and patient body surface area) is \> 1.3;
* Subjects with aortic root enlargement, where the ratio between the diameter of the sino-tubular junction and the annulus diameter is \> 1.3;
* Subjects with myocardial infarct \< =90 days;
* Subjects with known hypersensitivity to nickel alloys.

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No